The drugs recommended by clinical guidelines on HF were less frequently dispensed in women compared to men, such as beta-blocking agents (BB, 30.8% vs. 33.6%, p < 0.001), angiotensin-converting enzyme (ACE) inhibitors (25.8% vs. 33.1%, p < 0.001), and aldosterone antagonists (23.7% vs. 28.7%, p < 0.001), with the exception of angiotensin II receptor blockers (ARB, 23.8% vs. 21.0%, p < 0.001). The gene discussed is ACE; the disease is hydrops fetalis.